



City Research Online

City, University of London Institutional Repository

Citation: Fleming, T., Lucassen, M., Christopher, F., Parag, V., Bullen, C., Merry, S., Matthew, S. & Stasiak, K. (2025). Nationwide implementation of unguided cognitive behavioural therapy for adolescent depression: An observational study of SPARX. JMIR,

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/35161/>

Link to published version:

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Title

Nationwide implementation of unguided cognitive behavioural therapy for adolescent depression: An observational study of SPARX

Abstract

Background: Internet-based cognitive behavioural therapy (iCBT) interventions are effective in clinical trials; however, iCBT implementation data are seldom reported.

Objective: To evaluate uptake, adherence and changes in symptoms of depression for 12–19-year-olds using an unguided pure self-help iCBT intervention ('SPARX') during the first seven years of it being publicly available without referral in Aotearoa New Zealand (NZ).

Methods: SPARX is a seven-module, self-help intervention designed for adolescents with mild to moderate depression. It is freely accessible to anyone with a NZ Internet Protocol (IP) address, without the need for a referral, and is delivered in an unguided 'serious game' format. The NZ implementation of SPARX includes one symptom measure—the Patient Health Questionnaire adapted for Adolescents (PHQ-A)—which is embedded at the start of modules 1, 4, and 7. We report on uptake, the number of modules completed, and changes in depressive symptoms as measured by the PHQ-A.

Results: In total, 21,320 12–19-year-olds (approximately 2% of NZ 12-19-year-olds) registered to use SPARX. Of these, 63.6% started SPARX (n=13,564; 62.7% female, 31.4% male and 5.9% another gender identity or gender not specified; 64.4% New Zealand European, 14.3% Māori, 8.9% Asian, 3.7% Pacific, and 8.4% another ethnic identity; mean age 14.9 years). The mean PHQ-A at baseline was 13.6 (SD=7.7) with 16.1% reporting no or minimal symptoms, 37.4% reporting mild to moderate symptoms (i.e., the target group) and 46.7% reporting moderately severe or severe symptoms. Among those who started, 51% completed Module 1; 7% completed at least 4 modules and 3% completed all 7 modules. The severity of symptoms reduced from baseline to module 4 and 7. Mean and standard deviation PHQ-A scores for baseline, module 4 and module 7 for those who completed 2 or more assessments were 14.0 (7.0); 11.8 (7.9); and 10.5 (8.5) respectively; mean difference module 1 to 4, 2.2, $p<0.0001$; mean difference module 1 to 7, 3.6 $p<0.0001$. Corresponding effect sizes were 0.38 (Module 1 to 4) and 0.51 (Module 1 to 7).

Conclusions: SPARX reached a meaningful proportion of the adolescent population. The effect size for those who engaged with it was comparable to trial results. However, completion was low. Key challenges included logistical barriers such as slow download speeds and compatibility with some devices. Ongoing attention to rapidly evolving technologies and engagement are required. Real-world implementation analyses offer important insights for understanding and improving the impact of evidence-based digital tools and should be routinely reported.

Introduction

Adolescent depression is common and disabling [1,2]. Over 20% of Aotearoa New Zealand (NZ) secondary school adolescents, reported clinically significant depression symptoms in 2019 [3]. Evidence-based talking therapies, including cognitive behavioural therapy (CBT), are the recommended first line of treatment for mild to moderate depression [4]. However, 50-80% of young people with symptoms do not get treatment [5]. Internet-based cognitive behavioural therapy (iCBT) programs have been developed, partly in response to these challenges, and have been shown to be effective for the treatment of adult and adolescent depression [6].

Co-authors (TF, KS, ML, MS and SM) developed a computerised CBT intervention for adolescent depression called 'SPARX' (Smart, Positive, Active, Realistic, X-factor thoughts). SPARX performed at least as well as treatment as usual in a non-inferiority randomised controlled trial (RCT) with 187 adolescents seeking help for low mood or depression in primary care [7], and it was at least as effective for indigenous Māori adolescents as for non-Māori [8]. In smaller trials, SPARX was effective compared to waitlist control among adolescents excluded from mainstream education [9]; promising in an adapted 'Rainbow version' open trial among sexual and gender minority youth [10]; and appealing to a range of youth [11–13], although a Dutch version of SPARX was not more effective than a monitoring control or group-based CBT in an RCT in classroom settings [14]. A revised version of SPARX (SPARX-R), adjusted to include those without depression was not successfully implemented in a youth justice setting, where participants did not attend the youth justice programme regularly and few tried SPARX-R [15], however it was effective for the prevention of depression at six months follow-up in a large RCT (n=540) conducted in Australian secondary schools [16].

In 2014, the NZ Ministry of Health funded SPARX as an unguided self-help iCBT intervention. It was targeted to adolescents with mild to moderate depression but was freely available to anyone with an NZ Internet Protocol (IP) address with no referral required. In this paper, we explore outcomes for 12-19-year-olds who registered for SPARX from 2014-2021; the first seven years of SPARX being nationally available. There are some complexities. SPARX was originally trialled on CD-ROM's, rapid transition to online delivery was required for national

roll out. For the first years of national delivery, SPARX was only available via desktop or laptop computers (not smartphones or tablets), so users could register but not begin on a mobile device, and users were required to download a large file, which was not possible for some (e.g., due to firewalls or problematic internet speeds).

Despite, and in part *because* of operational challenges, it is valuable to examine implementation findings. While there are many trials of evidence-based iCBT programs in the peer-reviewed literature, there are few studies of how these programs perform in real-world settings [17,18]. In a 2018 systematic review, there were peer reviewed findings from just seven self-help interventions for depression, anxiety or enhancement of mood as implemented in real world settings [17], with these reporting much lower rates of retention than in trials of the same interventions. Moreover, routinely collected internet traffic data indicates median retention in publicly available mental health app-based programs is less than a quarter of that for the same programs evaluated in trials [18]. While there may be user benefits from even brief engagement [18], and, if initial uptake is high, even low rates of completion can have population impact, these data call for examination.

The research-to-implementation distinction is not unique to digital tools. For example, while six or more sessions of face-to-face CBT are recommended for initial treatment in many clinical guidelines [4], in practice there are considerable barriers, including a lack of services, limited resources and extensive waiting lists [19]. Internet-based interventions offer the ability to examine distinctions between ideal and real implementation, given the opportunities afforded by routine data collection in online delivery. In this paper, we report on the uptake, engagement and impact of SPARX by 12–19-year-olds in its implementation in the ‘real world’ as a pure self-help (i.e., unguided) intervention.

Methods

Study design

This was a purely observational retrospective cohort study of national implementation of SPARX iCBT in Aotearoa New Zealand. There were no recruitment or study procedures beyond analysis of anonymous self-reported data and automatically collected analytics for 12–19-year-old users who registered to use SPARX via the New Zealand website (www.sparx.org.nz) between 1st April 2014 and 30th September 2021. There were no data collected outside of the SPARX program.

Ethical considerations

All users, including minors, provided their own consent to use SPARX and for anonymous data to be analysed for evaluating and improving the program. Synchronous human-delivered supports via toll-free telephone, text or messaging services were available free of charge. Participants did not receive compensation or payments.

Parent/Guardian consent was not required for the use of SPARX as implemented in NZ. This decision was made by the funder (the NZ Ministry of Health) and provider (the New Zealand Institute of Health Innovation (NIHI) at the University of Auckland) in collaboration with national clinical and governance groups overseeing the SPARX rollout. The decision to allow minors to self-consent was grounded in clinical and ethical considerations. The risks associated with untreated depression and other mental health issues in young people are well documented [1] and parent engagement is a significant barrier to treatment for some [20, 21]. Recent New Zealand data underscores this point. Among male secondary school students who had attempted suicide in the past 12 months, only 36% had talked to a parent or family member about feeling bad [22]. Upon registration for SPARX, users agreed to 'get extra help' if SPARX was not helping or was not sufficient for their needs. The website and SPARX program included messaging encouraging young people to talk with family members and others, along with guidance on how to do so and where and how to access further support.

Parental/guardian consent was also not required for data to be used in this analysis. Requiring additional consent for use of routinely collected data can introduce selection bias in observational studies [23] and New Zealand National Ethical Standards for Health and Disability Research and Quality Improvement [24] and Health Information Governance Guidelines [25] allow for the use of non-identifiable health information such as this for research and evaluation purposes.

The study was approved the New Zealand Health and Disability Ethics Committee (HDEC) by Reference: 15/NTB/183) and is reported using STROBE criteria for STrengthening the Reporting of OBservational studies in Epidemiology [26].

Participants and setting

Automatically collected analytics from all 12–19-year-olds who registered for SPARX as implemented between 1st April 2014 and 30th September 2021 were analysed. There were no exclusion criteria beyond age group, registration and time period. Given the observational nature of this research, no pre-determined sample size was calculated. Instead, the size of the study was based on the number of adolescent users accessing SPARX from the start of the NZ-wide roll out of the program (1 April 2014), to just prior to the use of SPARX 2.0 (i.e., a new iteration of the intervention, 30 September 2021).

Participants could register for SPARX on any device with internet access and could open SPARX on a PC or laptop, or, from 2018, on a mobile device from any location via a NZ IP address. While there were barriers such as internet firewalls and download speeds (described under ‘Implementation Model’), the SPARX website was available more than 99.9% of the time and users could register and begin SPARX at any time during the seven-year study period. Exposure varied from registration only, to completion of all seven levels of SPARX with no limitations on time taken.

Intervention

The SPARX program has been described elsewhere [7]. In brief, it is a structured iCBT program which includes interpersonal skills and emotion regulation content. SPARX utilises a bi-centric frame of reference involving both explicit information giving and discovery or

implicit learning [7]. A guide (virtual therapist) introduces the program and ‘speaks’ directly with the user at the start and close of each of the seven modules, with scripted dialogue to support rapport, hope, engagement, consolidation and generalisation of therapeutic content. The core part of each module takes place in a game-like setting, where the user takes on challenges and solves problems to ‘restore the balance’ and solve problems in a fantasy world, allowing them to discover and rehearse CBT concepts and skills in a playful way as they progress. At the end of each module, users return to the guide to consolidate and review key concepts and to encourage the application of concepts and skills in everyday life with quizzes, open text questions and reflective exercises.

The therapeutic content of SPARX has also been described previously [7]. In summary, Module 1 focuses on building virtual rapport, with caring and welcoming words from the guide, the expression of hope and expectations of improvement (even if multiple steps are required). Psychoeducation about variation in mood and depression and how moods and feelings change is provided. Module 1 also includes how to find additional forms of support and it introduces relaxation breathing. Module 2 pertains to behavioural activation, and key prosocial communication skills. Module 3 focuses on dealing with strong emotions while Module 4 explores problem solving. Modules 5 and 6 relate to recognising and challenging unhelpful thoughts and growing realistic positive thoughts and action thinking. Finally, Module 7 integrates the included skills and concepts and includes additional strategies and resources for managing persistent challenges.

Implementation model

In 2014, the SPARX research team, in collaboration with the National Institute for Health Innovation at the University of Auckland, were the successful applicants for New Zealand Ministry of Health funding to deliver a youth e-therapy. A pure self-help delivery model, via a publicly available website with phone/text or webchat support through existing independent agencies, was developed in collaboration with government agencies and advisors. Governance and clinical oversight committees and processes were established. The SPARX program was rapidly adjusted from the CD-ROM version used in the initial randomised controlled trial, for online delivery with minor adaptations as outlined in Table 1. Promotion was undertaken, including presentations at meetings of health professionals

and school staff and via social media advertising targeting young people. Potential users visit the website which includes access to SPARX and an optional anonymous online PHQ-A [27] assessment which is presented as a 'Mood Quiz', to help users identify whether SPARX might help them. Those whose score on this optional measure indicates no or minimal symptoms are encouraged to try SPARX, to develop skills for any future challenges; those who score in the mild to moderate range are advised that SPARX may be a helpful tool for them; and those who score in the moderately severe or more severe range, or who indicate a risk of self-harm are advised to seek further support and try SPARX once they are safe. Those who wish to access SPARX (with or without completing the 'mood quiz' first and regardless of 'mood quiz' results) must register by entering an email address, creating a username and password, and answering brief demographic questions. They may opt to get automatic reminders by text and/or email and must agree to the terms of use. Once registered, users may begin the program on a PC or laptop, or, from 2018, on a mobile device. As users begin the first module of SPARX, they complete the first in-program PHQ-A and then progress through SPARX modules in the prescribed order at their own pace. In Module 1 users are welcomed to the program, advised to complete 1-2 modules per week, and are provided information on where to get extra help. Automatic email reminders are sent two and four weeks after the last use of SPARX for those who opted in for reminders and who had not completed the program.

Table 1: Changes to SPARX for national online implementation

The following key changes were made to SPARX from the research version delivered by CD-ROM in the 2012 RCT [7], for the national implementation of the program:

- A Likert scale for rating mood in all modules in the research version was replaced with the Patient Health Questionnaire Adapted for Adolescents (PHQ-A) towards the beginning of Modules 1, 4 and 7.
- A list of helping resources and prompts for how and where to seek help was provided on the on the SPARX website.
- Further messages to prompt help-seeking were added for those with high or deteriorating scores on PHQ-A and/or item 9 (indicative of a risk of self-harm), were added within SPARX.
- A dedicated free phone and text number for SPARX users was established. This was supported by a partner telephone and text counselling organisation, to provide a full-time back-up crisis service. Since 2017 users can also request chat-based support via the SPARX website (this is also provided by the partner agency).
- A summary screen for each module was added. This can be printed out and replaces a paper notebook provided with each CD-ROM in the initial SPARX trials.

There were logistical challenges in the first years of implementation, and technical updates were made over this time period. Initially users were required to download a large file to a computer (not a mobile device); these files were blocked by some firewalls and downloads were very slow in some settings. Changes in the interface between internet browsers and 'Unity Player' (i.e., the game platform used for SPARX) meant that only some internet browsers could be used in some time periods. Hence, some registrants could not begin SPARX. A version which could be played on mobile was first available in 2018, however it appeared as designed for computer and was hard to read and manipulate on mobile devices. A significantly update, SPARX Version 2.0, optimised for mobile use, became available after this study period in October 2021. Future analyses will compare SPARX 2.0 to data reported here.

Variables

Study variables were collected from routinely gathered user data and automatically collected analytics. User data requirements had been established with the Ministry of Health in order to allow service evaluation while minimising barriers to engaging with SPARX. These were self-reported demographics (age, gender, ethnicity and NZ region), and how registrants found out about SPARX (e.g. school or health professional), all entered by the user on registration, and the adolescent-modified Patient Health Questionnaire 9-item depression scale (PHQ-A) [27], embedded at the beginning of Modules 1, 4, and 7 only. There were no symptom measures in other modules, as youth consultation had indicated potential negative impacts of repeated measures on engagement. The PHQ-A is a robust tool for depression screening [27]. Response options range from never to nearly every day (scores of 0-3) and although not a diagnostic test per se the total scores can be grouped into five symptom levels: none (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). We report demographic data with gender categorised as female, male or transgender/intersex/or gender not specified; ethnicity categorised using the New Zealand census ethnicity prioritisation method and age categorised into 12-15 and 16-19 years. Automatically collected analytics are registrations (registering or signing up for SPARX), opening of the SPARX program (i.e. 'starting', or opening the program at least once, for any length of time), start and finish times for each module, and number of modules completed. Our primary outcome variable was PHQ-A score.

Statistical analyses

Summaries of continuous variables have been presented as means and standard deviations or medians and inter-quartiles for skewed data, while categorical variables have been presented as frequencies and percentages. The extent of the skewness was quantified using Pearson's coefficient of Skewness, ($3 * (\text{Mean} - \text{Median}) / \text{standard deviation}$). We interpreted values >0.5 as indicating strong positive skewness. For users who completed at least two of the three PHQ-A scores, the mean change in PHQ-A scores from baseline (module 1) to module 4, module 7 and the last available module (4 or 7) were analysed using Paired sample t-tests. The data was treated as normality distributed due to the number of users

included in the analyses [28]. Effect size was calculated by dividing the mean difference by the standard deviation of the difference (Cohen's *d* for paired samples *t*-test). Data were analysed with Statistical Package for the Social Sciences (SPSS) version 28.0 and the Statistical Analysis System (SAS) version 9.4.

Results

Between April 2014 and September 2021, 21,310 12–19-year-olds registered for SPARX. As shown in Table 2, the majority (64%), were female. Registrants could select as many ethnic identities as applied to them, with one ethnicity assigned for the purposes of analysis using the NZ census ethnicity prioritisation method [29]; 16% were indigenous Māori, 5% Pacific, 8% Asian, 63% were NZ European; and 8% another ethnicity. Two-thirds (67%) were 12 to 15 years of age. In total, 13,564 (64% of registrants), started SPARX ('starters'). There were significant differences in gender, ethnicity, age, and referral source for starters compared to registrants; with female, Māori, younger and school referred participants forming higher proportions of starters than they did of registrants (Table 2). The mean PHQ-A at the start of the program (beginning of Module 1) was 13.5 (SD =7.7), with 37% reporting mild or moderate symptoms (the target group); 47% reporting more severe symptoms and 16% reporting no to minimal symptoms, as shown in Table 2. School was the largest single point of referral to SPARX, 32% of those who started; with a professional (i.e., counsellor, doctor or nurse) referral being second, with 30%.

Table 2: Characteristics of 12–19-year-olds registering for and starting SPARX

| | Total registrations n (%) | Started SPARX | | |
|--|---------------------------------|---------------|--------------|-----------------------|
| | | No n (%) | Yes n (%) | Difference P-value |
| Total | 21,310 | 13,564 | 7,746 | |
| Gender | | | | <0.0001 |
| Female | 13,593 (63.8) | 8,499 (62.7) | 5,094 (65.8) | |
| Male | 6,507 (30.5) | 4,265 (31.4) | 2,242 (28.9) | |
| Transgender/intersex/or gender not specified | 1,210 (5.7) | 800 (5.9) | 410 (5.3) | |
| Prioritised ethnicity | | | | <0.0001 |
| Māori | 3,354 (15.7) | 1,941 (14.3) | 1,413 (18.2) | |
| Pacific | 985 (4.6) | 538 (4.0) | 447 (5.8) | |

| | | | | |
|------------------------------------|---------------|--------------|--------------|---------|
| Asian | 1,799 (8.4) | 1,202 (8.9) | 597 (7.7) | |
| Other | 1,796 (8.4) | 1,142 (8.4) | 654 (8.4) | |
| New Zealand European | 13,376 (62.8) | 8,741 (64.4) | 4,635 (59.8) | |
| Age | | | | <0.0001 |
| 12-15 years | 14,297 (67.1) | 8,908 (65.7) | 5,389 (69.6) | |
| 16-19 years | 70,13 (32.9) | 4,656 (34.3) | 2,357 (30.4) | |
| Mean (SD) | 14.8 (1.9) | 14.9 (1.9) | 14.6 (1.9) | <0.0001 |
| Referral source | | | | <0.0001 |
| School | 7,136 (33.5) | 4,340 (32.0) | 2,796 (36.1) | |
| Counsellor, doctor, or nurse | 5,924 (27.8) | 4,047 (29.8) | 1,877 (24.2) | |
| Friend | 1,370 (6.4) | 887 (6.5) | 483 (6.2) | |
| Google, Facebook, or advertisement | 3,090 (14.5) | 1,842 (13.6) | 1,248 (16.1) | |
| Other | 3,790 (17.8) | 2,448 (18) | 1,342 (17.3) | |
| Baseline PHQ-A | | | | - |
| Did not complete | - | | 1,248 | |
| Not depressed (0-4) | - | | 1,980 (16.1) | |
| Mild (5-9) | - | | 2,061 (16.7) | |
| Moderate (10-14) | - | | 2,548 (20.7) | |
| Moderately severe (15-19) | - | | 2,523 (20.5) | |
| Severe (20-27) | - | | 3,219 (26.1) | |

Of those who began SPARX ('starters', n= 13,564); 51% completed Module 1; 21% and 11% completed Modules 2 and 3 respectively; 7% completed Module 4 and 3% finished all seven modules as shown in Figure 1. These data represent a 41-77% retention at each module (also shown in Figure 1). Users spent a median time of 19 minutes per module, with interquartile range of 15 to 25 minutes. Among those who started the last module and have the module start time available (n=435), the median completion time was 12 days, with wide interquartile range of 2 to 42 days.

Figure 1: Engagement, April 2014 to September 2021




Table 3 provides the mean PHQ-A scores for modules 1, 4 and 7 and paired difference means. Paired t-tests show significant reductions in PHQ-A scores between module 1 and module 4 and between module 1 and module 7, as well as module 1 to last available measure (module 4 or 7) with $p < 0.0001$ for each of these. Effect sizes (Cohen's d) are 0.38 for those who complete the second PHQ-A only (at module 4); 0.51 for those who complete the PHQ-A at module 7 and 0.43 for baseline to last available score (module 4 or 7).

Table 3: PHQ-A score at baseline and modules 4 or 7 including Paired samples t-tests

| | N | Module 1 (baseline) mean (SD) | Comparison level mean (SD) | Paired difference mean (SD) | P-value | Effect size |
|---|-------|-------------------------------------|----------------------------------|-----------------------------------|---------|----------------|
| Module 1 to module 4 | 1,124 | 14.0 (7.4) | 11.8 (7.9) | 2.2 (5.7) | <0.0001 | 0.38 |
| Module 1 to module 7 | 473 | 14.1 (7.3) | 10.5 (8.5) | 3.6 (7.0) | <0.0001 | 0.51 |
| Module 1 to last available (module 4 or 7) | 1,124 | 14.0 (7.4) | 11.2 (8.1) | 2.8 (6.5) | <0.0001 | 0.43 |

Discussion

This article is among the first to analyse national implementation data from an evidence-based self-help intervention for adolescent depression. We present data on reach, engagement, and impact among the target age group (12- to 19-year-olds) from the first seven years of availability, beginning when SPARX was first offered without referral and at no cost to anyone with a New Zealand IP address. Between 2014 and 2021, approximately 2% of the national adolescent population [30] registered for SPARX, with strong uptake by Indigenous Māori. Participants who completed two or more PHQ-A assessments showed moderate improvements in depressive symptoms, with effect sizes comparable to face-to-face therapy [31-33] and consistent with findings from the original randomized controlled trial (RCT) of SPARX [7]. Despite the RCT being a pragmatic trial with minimal exclusion criteria and limited additional user contact beyond usual practice [7], real-world use of SPARX differed in key ways. Users varied in baseline symptom severity, progressed through the program at different paces, and completed the program at significantly lower rates. These differences highlight the complexities of implementation and the need to address real-world barriers to engagement. Two decades of research have shown that evidence-based digital therapies can be both effective and engaging in controlled settings [34,35]. However, implementation in real-world contexts remains a critical challenge. Analysis of implementation data offers important insights for informing improved impact in communities [35–39].

We have demonstrated that it is feasible to shift from the research setting to real world implementation in a relatively short time period (i.e., going from the publication of the original RCT findings in late 2012 to national roll-out in 2014) and to achieve sizeable population reach. The registration numbers demonstrate interest in the program. While many of those who registered did not begin the intervention, this still represents a major increase in access to evidence-based therapy at a national level. Many interventions fail to reach Indigenous and minoritised youth. The data presented here demonstrate interest from Māori young people. Although, given the disproportionate burden of distress experienced by Māori [40], ongoing recruitment efforts are indicated for improving equity. Further efforts are also indicated to reach Pacific adolescents given the uptake reported was

low compared to population numbers and reported distress among Pacific youth [41]. Gender minority adolescents, including transgender and gender questioning youth, form between 1-4% of the New Zealand secondary school population [42] with many reporting depressive symptoms and poor access to care [42]. It is pleasing to see this group having comparatively high engagement with SPARX (e.g., 207 transgender adolescent registrations) [43].

The retention of effect size from the RCT to unsupported implementation, as observed in individuals who undergo at least two assessments, is a notable finding. The efficacy of interventions often diminishes when applied in routine practice [44,45]. The use of computerized programs, which automate delivery, can mitigate decreases in treatment fidelity. Extensive meta-analyses and systematic reviews have established that computerized or internet-delivered therapies for depression can be as effective as face-to-face treatments under research conditions [6,46]. The effect sizes reported in this study underscore treatment effectiveness in the real world. However, there are important caveats. First, these are correlational findings which apply to those completing two or more assessments. Second, despite effect sizes matching or exceeding the average for psychotherapeutic treatments for adolescent depression [47] mean post-intervention scores remained clinically significant (over the cut off on the depression measure). These findings emphasize the importance of integrating evidence from both controlled studies and real-world implementation research. They also highlight the ongoing need to enhance the effectiveness of treatments for depression [47].

There were important differences in how public registrants used SPARX compared to the advice given on the website and within the program. Less than half of 12–19-year-old users (37%) were in the target group of mild to moderate symptoms of depression. Almost half reported more severe symptoms (47%) and hence were automatically advised to get more support, and then use SPARX alongside that extra help if desired. We do not know if they did this. Usage also diverged widely from the recommended rate of one to two modules per week, with most users working through the program much more quickly. It is important to note that users may not utilise internet-based programs as intended by developers, and hence to adjust communications to users, or, to adjust the programs themselves to fit user

behavior if needed. Adaptive, user-centered approaches (i.e. where programs are adjusted to fit user behavior and requirements), are common in the development of digital tools and ensure that interventions evolve to meet user behaviour rather than rigidly enforcing compliance with established protocols.

Adherence in this study was considerably lower than in the 2012 RCT where 86% of those randomized to SPARX completed at least Module 4 and 60% completed all seven modules [7]. Reduced adherence is not unusual in the translation of interventions from research to real world settings [48] as is seen in digital tools for mental health [18,49] and also in other areas including face-to-face therapy and medication [26, 50, 51]. For example, 0.5% of MoodGYM users completing a final assessment in the program as implemented, compared with 22.5% of participants in a trial of the same program [52]. Similarly, routinely collected internet traffic data shows that median retention in publicly available mental health apps is less than a quarter of that reported in trials [18]. Baumel et al. [53] propose that retention in digital self-help apps and programs should be considered in the context of their low barriers to entry. In contrast to the complexities of accessing face-to-face therapies, which may require considerable efforts to access, online self-help tools can often be accessed without a referral or an appointment, at any time, often within minutes and at no or low cost. Users may explore multiple tools before selecting one and some may be 'just looking' without the level of concern or motivation involved in getting to a clinical service [53]. Limited retention may be a shortcoming of digital tools, but alternatively, brief engagement might be all that some users need at the time. For example, those who complete only the first module of SPARX, still receive key psychoeducation and may benefit from understanding that they are not alone, that there are ways to improve mental health, and that further help is available through the program or other sources. Relatedly, there is evidence of benefits of very brief psychotherapeutic input, where single session therapies can be helpful [54]. Nevertheless, engagement rates reported here are disappointing. SPARX has not been designed or evaluated as a single session intervention.

Some limitations in engagement are likely to reflect logistical challenges. For example, users who only had access to a mobile device or who had slow internet speeds would not have been able to begin SPARX in the first years. Secondly, while the therapeutic content of

SPARX had been carefully evaluated, there were opportunities for an improved computer interface and human-computer interaction, for example in making movement of characters within the game easier and having increased save points within the game. Further, the presentation of SPARX as 'a game' may have increased appeal for some adolescents, by providing a non-threatening and engaging approach [55]; however, users accustomed to high-budget, rapidly evolving commercial games may have been disappointed [56,57]. These challenges highlight the importance of ongoing technological updates, regular user experience reviews and ongoing attention to communications about digital tools to target users. An updated version, SPARX 2.0, with enhanced graphics and gameplay and an updated website was launched in 2023 and data will be reported in future analyses. Further analyses of SPARX onboarding and user experience are underway. Blended care or guided approaches, where iCBT is provided alongside face-to-face therapy or with a therapist or e-coach input by email, text or telephone support typically (although not always) yields improved retention in comparison to pure self-help [58]. However, these options also bring increased costs and may reduce appeal for those who want anonymous help or do not want to talk to professionals, an important consideration given so many adolescents with depressive symptoms do not seek professional help [5].

There are important limitations in this study. Seven-years of data have been presented. However, this is an observational study: the data are within subject, as such there is no comparison group. Importantly, the results are correlational, findings maybe confounded by spontaneous improvements in PHQ-A scores. Further it is possible that the participants who were particularly motivated were more likely to both improve and to complete a higher number of modules of SPARX. These findings should therefore be considered alongside those from experimental studies with control groups. There is also no follow up of those who did not engage and there is only self-reported data pertaining to a single screening measure. Adolescents who completed the PHQ-A on the SPARX website and then immediately began SPARX progressing rapidly through modules would have completed the measure twice within a short time, potentially affecting their responses. While the authors include the co-developers of SPARX or those directly involved in its dissemination, the study plans and results have been reviewed by advisory groups. Implementation issues arose that were specific to this time period and this particular intervention, hence caution should be

exercised in considering implications for other settings. At the same time, there are few studies of this nature, and the findings highlight valuable opportunities for improving the real-world impact of digital interventions.

We have shown that it is possible to roll-out iCBT interventions nationally for adolescent depression and significantly increase access to evidence-based therapies in the population. However, this requires ongoing efforts to optimise impact. Reach can be supported by ongoing promotion to users and stakeholders via advertising, training, relationships with providers and via local champions [38]. Improving engagement also requires continued attention. There are many opportunities here, including the ethical use of Artificial Intelligence/AI. There are examples of effective or promising approaches in: the use of single session interventions [54,59]; the use of brief, just in time 'micro interventions' [53]; increased use of social or automated support including chatbots, chatrooms, AI and text support [38]; enhanced personalisation [49] and cultural responsiveness [38]; developments in telepresence and gamification [60]; increased use of persuasive design [61]; strong co-design, including increased building of digital tools to match how young people use the internet for their own wellbeing [62]; increased use of promotions, marketing and champions [38]; and, increased integration as part of pathways to care and mental health ecosystems [63]. Rigorously testing these innovations in research settings *and* analysing and reporting implementation data will be important for rapid and ethical development in the field and to assist in improving mental health outcomes in communities.

Conclusion

Given the barriers to mental health treatment for young people, free and private access to evidence-based digital therapy, is essential. Programs which can be made freely available to large numbers of users around the clock are critical components of a comprehensive contemporary mental health system. To optimise the impact of these tools, implementation data should be routinely reported, and ongoing promotion, updates and development should be prioritised. We propose that providers of evidence-based digital tools, such as iCBT, should routinely report implementation data, and not trial data alone, so that the sector can understand and optimise the health impacts of digital mental health interventions in the real world.

References

- [1] Clayborne ZM, Varin M, Colman I. Systematic Review and Meta-Analysis: Adolescent Depression and Long-Term Psychosocial Outcomes. *J Am Acad Child Adolesc Psychiatry* 2019;58:72–9.
<https://doi.org/10.1016/j.jaac.2018.07.896>.
- [2] Shorey S, Ng ED, Wong CHJ. Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis. *British Journal of Clinical Psychology* 2022;61:287–305.
<https://doi.org/10.1111/bjc.12333>.
- [3] Sutcliffe K, Ball J, Clark TC, Archer D, Peiris-John R, Crengle S, et al. Rapid and unequal decline in adolescent mental health and well-being 2012–2019: Findings from New Zealand cross-sectional surveys. *Australian & New Zealand Journal of Psychiatry* 2023;57:264–82.
<https://doi.org/10.1177/00048674221138503>.
- [4] National Institute for Health and Care Excellence. Depression in children and young people: identification and management NICE guideline [NG134]. London: 2019.
- [5] Radez J, Reardon T, Creswell C, Lawrence PJ, Evdoka-Burton G, Waite P. Why do children and adolescents (not) seek and access professional help for their mental health problems? A systematic review of quantitative and qualitative studies. *Eur Child Adolesc Psychiatry* 2021;30:183–211.
<https://doi.org/10.1007/s00787-019-01469-4>.
- [6] Karyotaki E, Efthimiou O, Miguel C, Maas genannt Bermpohl F, Furukawa TA, Cuijpers P, et al. Internet-Based Cognitive Behavioral Therapy for Depression. *JAMA Psychiatry* 2021;78:361.
<https://doi.org/10.1001/jamapsychiatry.2020.4364>.
- [7] Merry SN, Stasiak K, Shepherd M, Frampton C, Fleming T, Lucassen MFG. The effectiveness of SPARX, a computerised self help intervention for adolescents seeking help for depression: randomised controlled non-inferiority trial. *BMJ* 2012;344:e2598–e2598. <https://doi.org/10.1136/bmj.e2598>.

- [8] Shepherd M. An investigation into the design, applicability and evaluation of a computerised cognitive behavioural therapy programme-SPARX for Māori young people experiencing mild to moderate depression. The University of Auckland, 2011.
- [9] Fleming T, Dixon R, Frampton C, Merry S. A Pragmatic Randomized Controlled Trial of Computerized CBT (SPARX) for Symptoms of Depression among Adolescents Excluded from Mainstream Education. *Behavioural and Cognitive Psychotherapy* 2012;40:529–41. <https://doi.org/10.1017/S1352465811000695>.
- [10] Lucassen MFG, Merry SN, Hatcher S, Frampton CMA. Rainbow SPARX: A Novel Approach to Addressing Depression in Sexual Minority Youth. *Cogn Behav Pract* 2015;22:203–16. <https://doi.org/10.1016/j.cbpra.2013.12.008>.
- [11] Shepherd M, Merry S, Lambie I, Thompson A. Indigenous Adolescents' Perception of an eMental Health Program (SPARX): Exploratory Qualitative Assessment. *JMIR Serious Games* 2018;6:e13. <https://doi.org/10.2196/games.8752>.
- [12] Lucassen MF, Hatcher S, Fleming TM, Stasiak K, Shepherd MJ, Merry SN. A qualitative study of sexual minority young people's experiences of computerised therapy for depression. *Australasian Psychiatry* 2015;23:268–73. <https://doi.org/10.1177/1039856215579542>.
- [13] Fleming T, Lucassen M, Stasiak K, Shepherd M, Merry S. The impact and utility of computerised therapy for educationally alienated teenagers: The views of adolescents who participated in an alternative education-based trial. *Clinical Psychologist* 2016;20:94–102. <https://doi.org/10.1111/cp.12052>.
- [14] Poppelaars M, Tak YR, Lichtwarck-Aschoff A, Engels RCME, Lobel A, Merry SN, et al. A randomized controlled trial comparing two cognitive-behavioral programs for adolescent girls with subclinical depression: A school-based program (Op Volle Kracht) and a computerized program (SPARX). *Behaviour Research and Therapy* 2016;80:33–42. <https://doi.org/10.1016/j.brat.2016.03.005>.
- [15] Fleming TM, Gillham B, Bavin LM, Stasiak K, Lewycka S, Moore J, et al. SPARX-R computerized therapy among adolescents in youth offenders' program: Step-

wise cohort study. *Internet Interv* 2019;18:100287.

<https://doi.org/10.1016/j.invent.2019.100287>.

- [16] Perry Y, Werner-Seidler A, Calear A, Mackinnon A, King C, Scott J, et al. Preventing Depression in Final Year Secondary Students: School-Based Randomized Controlled Trial. *J Med Internet Res* 2017;19:e369. <https://doi.org/10.2196/jmir.8241>.
- [17] Fleming T, Bavin L, Lucassen M, Stasiak K, Hopkins S, Merry S. Beyond the Trial: Systematic Review of Real-World Uptake and Engagement With Digital Self-Help Interventions for Depression, Low Mood, or Anxiety. *J Med Internet Res* 2018;20:e199. <https://doi.org/10.2196/jmir.9275>.
- [18] Baumel A, Muench F, Edan S, Kane JM. Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis. *J Med Internet Res* 2019;21:e14567. <https://doi.org/10.2196/14567>.
- [19] O'Brien D, Harvey K, Howse J, Reardon T, Creswell C. Barriers to managing child and adolescent mental health problems: a systematic review of primary care practitioners' perceptions. *British Journal of General Practice* 2016;66:e693–707. <https://doi.org/10.3399/bjgp16X687061>.
- [20] Rasmussen E, Shannon K, Pitchford, B. Adolescents' Disclosure of Mental Illness to Parents: Preferences and Barriers. *Health Communication* 2020; 37346–355. <https://doi.org/10.1080/10410236.2020.1839201>.
- [21] Roulston C, Ahuvia I, Chen S, Fassler J, Fox K, Schleider J. "My family won't let me." Adolescent-reported barriers to accessing mental health care. *J Res Adolesc.* 2025;35(1):e70013. doi: 10.1111/jora.70013.
- [22] Peiris-John R, Ball J, Clark T, Fleming T, and the Adolescent Health Research Group (2024). Youth Mental Health Needs and Opportunities: Leveraging 25 Years of Research from the Youth2000 survey series. The University of Auckland and Victoria University of Wellington, 2024.
- [23] Kho M, Duffett M, Willison D, Cook D, Brouwers M. Written informed consent and selection bias in observational studies using medical records: systematic review. *BMJ.* 2009;338:b866. doi: 10.1136/bmj.b866.

- [24] National Ethics Advisory Committee. National Ethical Standards for Health and Disability Research and Quality Improvement. Wellington: Ministry of Health: 2019.
- [25] Health Information Standards Organisation (HISO), Ministry of Health - Manatū Hauora. HISO 10064:2017 Health Information Governance Guidelines. Wellington: Ministry of Health: 2017.
- [26] Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *International Journal of Surgery* 2014;12:1500–24. <https://doi.org/10.1016/j.ijsu.2014.07.014>.
- [27] Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. *BMJ* 2019;l1781. <https://doi.org/10.1136/bmj.l1781>.
- [28] Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets. *Annu Rev Public Health*. 2002;23:151-69. doi: 10.1146/annurev.publhealth.23.100901.140546. PMID: 11910059.
- [29] Yao ES, Bullen P, Meissel K, Tiatia J, Fleming T, Clark TC. Effects of Ethnic Classification on Substantive Findings in Adolescent Mental Health Outcomes. *J Youth Adolesc* 2022;51:1581–96. <https://doi.org/10.1007/s10964-022-01612-6>.
- [30] Statistics New Zealand (Stats NZ). National population estimates: At 30 June 2022 Available from: <https://www.stats.govt.nz/information-releases/national-population-estimates-at-30-june-2022/> [Accessed June 30, 2024] .
- [31] Klein JB, Jacobs RH, Reinecke MA. Cognitive-Behavioral Therapy for Adolescent Depression: A Meta-Analytic Investigation of Changes in Effect-Size Estimates. *J Am Acad Child Adolesc Psychiatry* 2007;46:1403–13. <https://doi.org/10.1097/chi.0b013e3180592aaa>.
- [32] Wuthrich VM, Zagic D, Dickson SJ, McLellan LF, Chen JT-H, Jones MP, et al. Effectiveness of Psychotherapy for Internalising Symptoms in Children and Adolescents When Delivered in Routine Settings: A Systematic Review and

Meta-analysis. *Clin Child Fam Psychol Rev* 2023;26:824–48.

<https://doi.org/10.1007/s10567-023-00433-8>.

- [33] Kolovos S, van Tulder MW, Cuijpers P, Prigent A, Chevreul K, Riper H, et al. The effect of treatment as usual on major depressive disorder: A meta-analysis. *J Affect Disord* 2017;210:72–81. <https://doi.org/10.1016/j.jad.2016.12.013>.
- [34] Baños RM, Herrero R, Vara MD. What is the Current and Future Status of Digital Mental Health Interventions? *Span J Psychol* 2022;25:e5. <https://doi.org/10.1017/SJP.2022.2>.
- [35] Mohr DC, Lyon AR, Lattie EG, Reddy M, Schueller SM. Accelerating Digital Mental Health Research From Early Design and Creation to Successful Implementation and Sustainment. *J Med Internet Res* 2017;19:e153. <https://doi.org/10.2196/jmir.7725>.
- [36] Burger F, Neerincx MA, Brinkman W-P. Technological State of the Art of Electronic Mental Health Interventions for Major Depressive Disorder: Systematic Literature Review. *J Med Internet Res* 2020;22:e12599. <https://doi.org/10.2196/12599>.
- [37] Mohr DC, Azocar F, Bertagnolli A, Choudhury T, Chrisp P, Frank R, et al. Banbury Forum Consensus Statement on the Path Forward for Digital Mental Health Treatment. *Psychiatric Services* 2021;72:677–83. <https://doi.org/10.1176/appi.ps.202000561>.
- [38] Fleming T, et al. Digital Tools for Mental Health and Wellbeing: Opportunities & Impact. Findings from the literature and community research. Wellington: Te Hīringa Hauora | Health Promotion Agency; 2021.
- [39] Meyerhoff J, Kornfield R, Lattie EG, Knapp AA, Kruzan KP, Jacobs M, et al. From formative design to service-ready therapeutic: A pragmatic approach to designing digital mental health interventions across domains. *Internet Interv* 2023;34:100677. <https://doi.org/10.1016/j.invent.2023.100677>.
- [40] Clark TC, Ball J, Fenaughty J, Drayton B, Fleming T (Terry), Rivera-Rodriguez C, et al. Indigenous adolescent health in Aotearoa New Zealand: Trends, policy and advancing equity for rangatahi Maori, 2001–2019. *Lancet Reg Health West Pac* 2022;28:100554. <https://doi.org/10.1016/j.lanwpc.2022.100554>.

- [41] Sutcliffe K, Wilson M, Clark TC, Crengle S, Fleming T. Distinct profiles of mental health need and high need overall among New Zealand adolescents – Cluster analysis of population survey data. *Australian & New Zealand Journal of Psychiatry* 2024;58:678–92. <https://doi.org/10.1177/00048674241243262>.
- [42] Clark TC, Lucassen MFG, Bullen P, Denny SJ, Fleming TM, Robinson EM, et al. The Health and Well-Being of Transgender High School Students: Results From the New Zealand Adolescent Health Survey (Youth’12). *Journal of Adolescent Health* 2014;55:93–9. <https://doi.org/10.1016/j.jadohealth.2013.11.008>.
- [43] Lucassen MF, Stasiak K, Fleming T, Frampton C, Perry Y, Shepherd M, et al. Computerized cognitive behavioural therapy for gender minority adolescents: Analysis of the real-world implementation of SPARX in New Zealand. *Australian & New Zealand Journal of Psychiatry* 2021;55:874–82. <https://doi.org/10.1177/0004867420976846>.
- [44] Breitenstein SM, Gross D, Garvey CA, Hill C, Fogg L, Resnick B. Implementation fidelity in community-based interventions. *Res Nurs Health* 2010;33:164–73. <https://doi.org/10.1002/nur.20373>.
- [45] Ginsburg LR, Hoben M, Easterbrook A, Anderson RA, Estabrooks CA, Norton PG. Fidelity is not easy! Challenges and guidelines for assessing fidelity in complex interventions. *Trials* 2021;22:372. <https://doi.org/10.1186/s13063-021-05322-5>.
- [46] Mamukashvili-Delau M, Koburger N, Dietrich S, Rummel-Kluge C. Long-Term Efficacy of Internet-Based Cognitive Behavioral Therapy Self-Help Programs for Adults With Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials. *JMIR Ment Health* 2023;10:e46925. <https://doi.org/10.2196/46925>.
- [47] Eckshtain D, Kuppens S, Ugueto A, Ng MY, Vaughn-Coaxum R, Corteselli K, Weisz JR. Meta-Analysis: 13-Year Follow-up of Psychotherapy Effects on Youth Depression. *J Am Acad Child Adolesc Psychiatry*. 2020;59(1):45-63. doi: 10.1016/j.jaac.2019.04.002.
- [48] National Institute of Health and Care Excellence. NICE real-world evidence framework Corporate document [ECD9]. London: NICE; 2022.

- [49] Lipschitz JM, Pike CK, Hogan TP, Murphy SA, Burdick KE. The Engagement Problem: a Review of Engagement with Digital Mental Health Interventions and Recommendations for a Path Forward. *Curr Treat Options Psychiatry* 2023;10:119–35. <https://doi.org/10.1007/s40501-023-00297-3>.
- [50] Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. *Nat Rev Drug Discov* 2023;22:387–409. <https://doi.org/10.1038/s41573-023-00670-0>.
- [51] Unni EJ, Gupta S, Sternbach N. Reasons for non-adherence with antidepressants using the Medication Adherence Reasons Scale in five European countries and United States. *J Affect Disord* 2024;344:446–50. <https://doi.org/10.1016/j.jad.2023.10.010>.
- [52] Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: randomised controlled trial. *BMJ* 2004;328:265–0. <https://doi.org/10.1136/bmj.37945.566632.EE>.
- [53] Baumel A, Fleming T, Schueller SM. Digital Micro Interventions for Behavioral and Mental Health Gains: Core Components and Conceptualization of Digital Micro Intervention Care. *J Med Internet Res* 2020;22:e20631. <https://doi.org/10.2196/20631>.
- [54] Schleider JL, Weisz JR. Little Treatments, Promising Effects? Meta-Analysis of Single-Session Interventions for Youth Psychiatric Problems. *J Am Acad Child Adolesc Psychiatry* 2017;56:107–15. <https://doi.org/10.1016/j.jaac.2016.11.007>.
- [55] Fleming TM, Bavin L, Stasiak K, Hermansson-Webb E, Merry SN, Cheek C, et al. Serious Games and Gamification for Mental Health: Current Status and Promising Directions. *Front Psychiatry* 2017;7. <https://doi.org/10.3389/fpsy.2016.00215>.
- [56] Fleming T, Lucassen M, Stasiak K, Sutcliffe K, Merry S. Technology Matters: SPARX – computerised cognitive behavioural therapy for adolescent depression in a game format. *Child Adolesc Ment Health* 2021;26:92–4. <https://doi.org/10.1111/camh.12444>.

- [57] Fleming T, Merry S, Stasiak K, Hopkins S, Patolo T, Ruru S, et al. The Importance of User Segmentation for Designing Digital Therapy for Adolescent Mental Health: Findings From Scoping Processes. *JMIR Ment Health* 2019;6:e12656. <https://doi.org/10.2196/12656>.
- [58] Krieger T, Bur OT, Weber L, Wolf M, Berger T, Watzke B, et al. Human contact in internet-based interventions for depression: A pre-registered replication and meta-analysis of randomized trials. *Internet Interv* 2023;32:100617. <https://doi.org/10.1016/j.invent.2023.100617>.
- [59] Osborn TL, Rodriguez M, Wasil AR, Venturo-Conerly KE, Gan J, Alemu RG, et al. Single-session digital intervention for adolescent depression, anxiety, and well-being: Outcomes of a randomized controlled trial with Kenyan adolescents. *J Consult Clin Psychol* 2020;88:657–68. <https://doi.org/10.1037/ccp0000505>.
- [60] Fleming T, Poppelaars M, Thabrew H. The role of gamification in digital mental health. *World Psychiatry* 2023;22:46–7. <https://doi.org/10.1002/wps.21041>.
- [61] Alqahtani F, Al Khalifah G, Oyeboode O, Orji R. Apps for Mental Health: An Evaluation of Behavior Change Strategies and Recommendations for Future Development. *Front Artif Intell* 2019;2. <https://doi.org/10.3389/frai.2019.00030>.
- [62] Thabrew H, Fleming T, Hetrick S, Merry S. Co-design of eHealth Interventions With Children and Young People. *Front Psychiatry* 2018;9. <https://doi.org/10.3389/fpsy.2018.00481>.
- [63] Merry SN, Cargo T, Christie G, Donkin L, Hetrick S, Fleming T, et al. Debate: Supporting the mental health of school students in the COVID-19 pandemic in New Zealand – a digital ecosystem approach. *Child Adolesc Ment Health* 2020;25:267–9. <https://doi.org/10.1111/camh.12429>.